JCO Early Release, published online ahead of print Aug 18 2008
Journal of Clinical Oncology, 10.1200/JCO.2008.16.4707
Received January 28, 2008
Accepted June 6, 2008
Zoledronic Acid Prevents Bone Loss in Premenopausal Women Undergoing Adjuvant Chemotherapy for Early-Stage Breast Cancer
Dawn L. Hershman,* Donald J. McMahon, Katherine D. Crew, Serge Cremers, Dinaz Irani, Gina Cucchiara, Lois Brafman, and Elizabeth Shane
From the Department of Medicine; Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons; and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY.
* To whom correspondence should be addressed. E-mail: dlh23{at}columbia.edu
Purpose: Adjuvant chemotherapy for breast cancer (BC) may be associated with increased rates of bone loss and decreased bone mineral density (BMD) and may lead to premature osteoporosis and increased fracture risk. We examined whether zoledronic acid (ZA) prevents bone loss in premenopausal women receiving chemotherapy for early-stage BC.
Patients and Methods: This study is a randomized, double-blind, multicenter, phase III trial comparing ZA (4 mg intravenously every 3 months) versus placebo for 1 year. Premenopausal women underwent serial BMD measurements before initiating chemotherapy and at 6 and 12 months. The primary outcome was percent change in lumbar spine (LS) BMD at 6 months. Secondary outcomes were percent change at any BMD site and markers of bone turnover at 12 months. Linear mixed model analysis for repeated measures was performed.
Results: Of 101 women who were randomly assigned and completed baseline evaluation, 96 completed the 6-month evaluation, and 85 completed the 12-month evaluation. Baseline characteristics were comparable between the groups. Mean age was 42 years. Placebo was associated with significant decline in LS BMD at both 6 (2.4%) and 12 (4.1%) months. Similarly, total hip BMD declined by 0.8% at 6 months and 2.6% at 12 months. In contrast, BMD remained stable in ZA patients (P < .0001 compared with placebo).
Conclusion: Premenopausal women receiving chemotherapy for BC sustained significant bone loss at the LS and hip, whereas BMD remained stable in women who received ZA. Administration of ZA during the first year of chemotherapy is an effective and well-tolerated strategy for preventing bone loss.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Gnant, P. Blaha, P. Dubsky, R. Exner, F. Fitzal, E. Sporn, P. Panhofer, A. Dal Borgo, S. Bigenzahn, G. Steger, et al.
Review: Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?
Therapeutic Advances in Medical Oncology,
November 1, 2009;
1(3):
123 - 136.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. D. Crew, E. Shane, S. Cremers, D. J. McMahon, D. Irani, and D. L. Hershman
High Prevalence of Vitamin D Deficiency Despite Supplementation in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy
J. Clin. Oncol.,
May 1, 2009;
27(13):
2151 - 2156.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Kataja, M. Castiglione, and On behalf of the ESMO Guidelines Working Group
Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc.,
May 1, 2009;
20(suppl_4):
iv10 - iv14.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Paterson and T. Baker
Bisphosphonates and Bone Turnover in Premenopausal Women Receiving Adjuvant Chemotherapy
J. Clin. Oncol.,
March 1, 2009;
27(7):
1005 - 1006.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Lustberg and C. L. Shapiro
Physical Challenges of Adult Cancer Survivors
ASCO Educational Book,
January 1, 2009;
2009(1):
564 - 569.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Zoledronic Acid for Preventing Bone Loss in Young Breast Cancer Patients
Journal Watch Women's Health,
October 23, 2008;
2008(1023):
3 - 3.
[Full Text]
|
|
|
|
